Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial | Zendy

John Raemaekers | Zendy; Marc André | Zendy; Massimo Federico | Zendy; T. Girinsky | Zendy; Oumédaly Reman | Zendy; Ercole Brusamolino | Zendy; Pauline Brice | Zendy; Christophe Fermé | Zendy; Richard van der Maazen | Zendy; Manuel Gotti | Zendy; Réda Bouabdallah | Zendy; Catherine Sebban | Zendy; Yolande Lievens | Zendy; Alessandro Re | Zendy; Aspasia Stamatoullas | Zendy; F. Morschhauser | Zendy; Pieternella J. Lugtenburg | Zendy; Elisabetta Abruzzese | Zendy; Philippe Olivier | Zendy; Olivier Casasnovas | Zendy; Gustaaf van Imhoff | Zendy; Tiana Raveloarivahy | Zendy; Monica Bellei | Zendy; Thierry Van der Borght | Zendy; Stéphane Bardet | Zendy; Annibale Versari | Zendy; Martin Hutchings | Zendy; Michel Meignan | Zendy; Catherine Fortpied | Zendy

Open Access

Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial

Author(s) -

John Raemaekers,

Marc André,

Massimo Federico,

T. Girinsky,

Oumédaly Reman,

Ercole Brusamolino,

Pauline Brice,

Christophe Fermé,

Richard van der Maazen,

Manuel Gotti,

Réda Bouabdallah,

Catherine Sebban,

Yolande Lievens,

Alessandro Re,

Aspasia Stamatoullas,

F. Morschhauser,

Pieternella J. Lugtenburg,

Elisabetta Abruzzese,

Philippe Olivier,

Olivier Casasnovas,

Gustaaf van Imhoff,

Tiana Raveloarivahy,

Monica Bellei,

Thierry Van der Borght,

Stéphane Bardet,

Annibale Versari,

Martin Hutchings,

Michel Meignan,

Catherine Fortpied

Publication year - 2014

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2013.51.9298

Subject(s) - medicine , abvd , stage (stratigraphy) , positron emission tomography , radiation therapy , dacarbazine , randomized controlled trial , vinblastine , hazard ratio , nuclear medicine , clinical trial , radiology , confidence interval , vincristine , chemotherapy , paleontology , biology , cyclophosphamide

Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET) scan could be used to adapt treatment. Therefore, we started the randomized EORTC/LYSA/FIL Intergroup H10 trial evaluating whether involved-node radiotherapy (IN-RT) could be omitted without compromising progression-free survival in patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog